

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C12Q 1/68, 1/00, G01N 33/53 G01N 33/566, 33/559, C12P 21/06	<b>A1</b>	<b>(11) International Publication Number:</b> WO 93/04204 <b>(43) International Publication Date:</b> 4 March 1993 (04.03.93)
<b>(21) International Application Number:</b> PCT/US92/07121 <b>(22) International Filing Date:</b> 21 August 1992 (21.08.92)  <b>(30) Priority data:</b> 749,000 23 August 1991 (23.08.91) US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 749,000 (CIP) Filed on 23 August 1991 (23.08.91)  <b>(71) Applicant (for all designated States except US):</b> ISIS PHARMACEUTICALS, INC. [US/US]; 2280 Faraday Avenue, Carlsbad, CA 92008 (US).	<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> ECKER, David, J. [US/US]; 1041 Saxony Road, Leucadia, CA 92024 (US). WYATT, Jacqueline [US/US]; 2202 Highland Drive, Carlsbad, CA 92008 (US). BRUICE, Thomas, W. [US/ US]; 6880 Shearwaters Drive, Carlsbad, CA 92008 (US). ANDERSON, Kevin [US/US]; 2772 La Gran Via, Carlsbad, CA 92009 (US). HANECAK, Ronnie, C. [US/US]; 24 Blake Court, Irvine, CA 92715 (US). VICKERS, Timothy [US/US]; 253 Luiseno Avenue, Oceanside, CA 92057 (US). DAVIS, Peter [US/US]; 2202 Highland Drive, Carlsbad, CA 92008 (US).  <b>(74) Agent:</b> CALDWELL, John, W.; Woodcock Washburn Kurtz Mackiewicz & Norris, One Liberty Place, 46th Floor, Philadelphia, PA 19103-7301 (US).  <b>(81) Designated States:</b> AU, BR, CA, FI, HU, JP, KR, NO, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).  <b>Published</b> <i>With international search report.</i>	

**(54) Title:** SYNTHETIC UNRANDOMIZATION OF OLIGOMER FRAGMENTS

**(57) Abstract**

Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled subunits are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.

RECEIVED  
STIC  
FOREIGN PATS DIV

MAR 9 1993

PAT & T.M. OFFICE

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	MI	Mali	UA	Ukraine
ES	Spain			US	United States of America

## SYNTHETIC UNRANDOMIZATION OF OLIGOMER FRAGMENTS

### FIELD OF THE INVENTION

This invention relates to the development of drugs and of biologically active diagnostics and research reagents. In particular, this invention relates to the synthetic unrandomization of oligomer fragments to determine fragments specifically active for target molecules.

### CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Serial No. 749,000 filed August 23, 1991, entitled "Synthetic Unrandomization of Oligomer Fragments" and assigned to the assignee of the present application. The entire disclosure of this application is incorporated by reference herein.

### BACKGROUND OF THE INVENTION

Oligomers may be designed which are useful for therapeutic, diagnostic and research applications. In the past, development of biologically active oligomer substances was often limited to the modification of known sequences, unit by unit, until a desired characteristic or efficacy was achieved. However, in addition to time drawbacks, protocols employing these types of methodologies are limiting in that the final product is based upon, and often not far removed from, the structure of the starting material.

Recently, new methods have been developed whereby drugs and biologically active substances can be "designed." A variety of combinatorial strategies have been described to

- 2 -

identify active peptides. Houghton, et al. *Nature* 1991, 354, 84; Lam, et al., *Nature* 1991, 354, 82; Owens, et al., *Biochem. Biophys. Res. Commun.* 1991, 181, 402; Fodor, et al., *Science* 1991, 251, 767; Geysen, et al., *Molecular Immunology* 1986, 23, 709; Zuckermann, et al., *Proc. Natl. Acad. Sci.* 1992, 89, 4505; Rutter, et al., U.S. 5,010,175 issued April 23, 1991.

Focusing on the field of nucleic acid--protein binding, combinatorial nucleic acid selection methods generally select for a specific nucleic acid sequence from a pool of random nucleic acid sequences based on the ability of selected sequences to bind to a target protein. The selected sequences are then commonly amplified and the selection process repeated until a few strong binding sequences are identified. These methods generally employ enzymatic steps within the protocol. Commonly T7 RNA polymerase and Taq I associated with polymerase chain reaction amplification methods are employed. One group recently identified a target sequence to the RNA-binding protein gp43. Tuerk and Gold, *Science* 1990 249, 505. Tuerk and Gold's "systematic evolution of ligands by exponential enrichment" (SELEX) method identified specifically bindable RNA sequences using four cycles of amplification of RNA sequences having variable portions therein and which were specifically bindable to gp43.

Another group designed DNA molecules which recognized the protease thrombin. Bock, et al., *Nature* 1992, 355, 564. This method involves the preparation of a population involving a random region flanked by known primer regions followed by PCR amplification and selection. Small molecule mimics of metabolic cofactors have been selectively recognized by RNA sequences in this manner by Ellington and Szostak, *Nature* 1990, 346, 818. These techniques were suggested to be useful to design oligonucleotide ligands, however their dependence upon enzymatic means for amplification and sequence determination limits their uses. Simpler methods for the identification of useful oligomers which are specifically bindable to target molecules and which express specific activity for target molecules are greatly

- 3 -

desired. Methods which are not dependent upon enzymatic means would simplify protocols as well as expand the range of substrates with which the protocols would be effective. For example, presently there are over one hundred nucleotide  
5 analogs available. Cook, P.D., *Anti-Cancer Drug Design* 1991, 6, 585 and Uhlmann, et al., *Chem. Rev.* 1990, 90, 544. Since not all analogs are amenable to enzymatic processes, a non-enzymatic means for determining useful oligomer sequences which are specifically bindable to target sequences is greatly  
10 desired. Such methods could determine oligomers which are specifically bindable, not only to natural RNA-binding proteins, but also to any protein, nucleic acid, or other target molecule.

Methods are also greatly desired for determining  
15 useful oligomer sequences having particular desired activity, not limited to binding of target molecules. Such activity may include, but is not limited to, enzymatic or catalytic activity.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1 is a schematic representation of the nucleotide sequence and secondary structure of the ras 47-base-pair stem/loop RNA.

Figure 2 is a gel image of a gel shift assay showing binding affinity of RNA oligonucleotides with ras 47-base-pair  
25 stem/loop RNA.

Figure 3 is a schematic representation of inhibition of cytomegalovirus activity by four different oligonucleotide sets. Compound set C had the greatest activity against cytomegalovirus

30 Figure 4 is a schematic representation of inhibition of influenza virus activity caused by four different oligonucleotide sets at concentration of 10  $\mu$ M and 100  $\mu$ M of oligonucleotide. Compound sets B and D had the greatest antiviral activities.

- 4 -

Figure 5A is a schematic representation of the nucleotide sequence and secondary structure of the HIV TAR element.

Figure 5B is a gel image showing binding affinity of four oligonucleotide sets for the HIV TAR element at four different oligonucleotide concentrations. The oligonucleotide set NNNA'NGNNNN (SEQ ID NO:2) had the greatest binding affinity.

Figure 6 is a schematic representation of the nucleotide sequence and secondary structure of the HIV gag-pol stem loop.

Figure 7 is a gel image showing the binding affinity of 100 pmoles of a phosphorothioate oligonucleotide set having the sequence NNNNTNNNN for the protein CD4 in the presence and absence of a competitor, dIdC. 100 pmoles exhibited binding which was visible at 0.5 and 1  $\mu$ G CD4.

Figure 8 is a gel image showing selection of an oligonucleotide with the highest affinity for a biotinylated target oligonucleotide. The "winner" sequence (top arrow) was evident through three rounds of the procedure. Lane 1 is the input material diluted 1:10. Lane 2 is the supernatant diluted 1:10. Lane 3 is the bound material. Lanes 4 and 5 are the supernatant (1:10 dilution) and bound material of round 2, respectively. Lanes 6 and 7 are the supernatant (1:10 dilution) and bound material of round 3, respectively. The top arrow indicates "winner" material. Randomer library material migrates to the position indicated by the bottom arrow.

#### SUMMARY OF THE INVENTION

Combinatorial strategies offer the potential to generate and screen extremely large numbers of compounds and to identify individual molecules with a desired binding specificity or pharmacological activity. This invention is directed to substantially non-enzymatic methods of determining oligomers which are specifically active for target molecules.

- 5 -

Such oligomers preferably exhibit desired activity such as enzymatic or catalytic activity as well as binding affinity.

Methods of the present invention are useful for the determination of oligomers which have specific activity for  
5 target molecule from a pool of primarily randomly assembled subunits. Said methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining the oligomer set having the greatest activity in an assay for desired activity.

10 Simplification of the pool occurs because, with each additional step of the methods, at least one additional position in the oligomer is determined. As a result, the possible number of different oligomer molecules in the pool decreases sequentially with the number of random positions  
15 remaining in the oligomer.

Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.

In one embodiment of the present invention, methods  
20 for making oligonucleotides having specific activity for a target molecule are provided. These methods involve preparing a group comprising a plurality of sets of oligonucleotides, each oligonucleotide comprising at least four base units, by defining a common position in the oligonucleotides of the sets  
25 and synthesizing said sets of oligonucleotides such that each set has a different base unit in said common position and the base units which are not in the common position are randomized. Each of the sets are then assayed for activity against the target molecule and the set having the greatest  
30 activity for the target molecule is selected.

In other embodiments of the present invention each group of oligonucleotides may be subfractionated to provide subfractions of the sets of oligonucleotides. Each subfraction may be assayed against the target molecule and the set from  
35 which the subfraction having the highest activity was derived is selected.

- 6 -

These methods further comprise preparing a further group comprising a plurality of sets of oligonucleotides, each of the sets having in the previously defined common position the base unit appearing in the previously defined common position in the previously selected set. Each of said further group of sets has a different base unit in an additional, defined common position. The base units in positions of the oligonucleotides which are not in a common position are randomized. In other embodiments of the invention this group may subfractionated to provide subfractions of the sets of oligonucleotides.

Each of said sets or subfractions of sets may be assayed for activity for the target molecule and the set having the highest activity, or the set from which the subfraction having the highest activity was derived, is selected. The preceding steps may be performed iteratively.

Methods of determining an oligonucleotide cassette having specific activity for a target molecule are also provided by the present invention. These methods involve preparing a group comprising a plurality of sets of oligonucleotides, each oligonucleotide comprising at least four base units, by defining a common position in the oligonucleotides of the sets and synthesizing said sets of oligonucleotides such that each set has a different base unit in said common position and the base units which are not in the common position are randomized. Each of the sets are then assayed for activity for a target molecule and the set having the greatest activity for the target molecule is selected. Thereafter, a further group is prepared comprising a plurality of sets of oligonucleotides, each of the sets having in the previously defined common position the base unit appearing in the previously defined common position in the previously selected set. Each of said further group of sets has a different base unit in an additional defined common position. The base units in positions of the oligonucleotides which are not in a defined common position are randomized. Each set of said further group is assayed for specific activity for the



- 7 -

target molecule and the set having the highest activity is selected. The preceding steps are performed iteratively to provide an oligonucleotide cassette having each position defined.

5           In other embodiments of the invention, methods for determining an oligonucleotide having specific activity for a target molecule are provided. Such methods comprise preparing a group comprising a plurality of sets of oligonucleotides, each of the oligonucleotides comprises at  
10 least one oligonucleotide cassette and at least one flanking region. A common position is defined in a flanking region of the oligonucleotides of the sets and the sets of oligonucleotides are synthesized such that each set has a different base unit in said common position and the base units  
15 which are not in the common position are randomized. Each of the sets are then assayed for activity for a target molecule and the set having the greatest activity for the target molecule is selected.

          These methods also may comprise preparing a further  
20 group comprising a plurality of sets of oligonucleotides, each of the sets having in the previously defined common position the base unit appearing in the previously defined common position in the previously selected set. Each of said further group of sets having a different base unit in an additional,  
25 defined common position in the flanking region. The base units in positions of the oligonucleotides which are not in a common position in the flanking region are randomized. Each of the sets of oligonucleotides are assayed for specific activity for the target molecule and the set having the highest activity  
30 is selected. The preceding steps may be and preferably are performed iteratively.

          In another embodiment of the present invention, methods for making polypeptides having specific activity for a target molecule are provided. These methods involve  
35 preparing a group comprising a plurality of sets of polypeptides, each polypeptide comprising at least four amino acids units by defining a common position in the polypeptides

- 8 -

of the sets and synthesizing said sets of polypeptides such that each set has a different amino acid unit in said common position, the amino acid units which are not in said common position being randomized. Each of the sets is then assayed  
5 for activity and the set having the most activity is selected.

In yet another embodiment of the present invention each group of polypeptides is subfractionated to provide subfractions of the sets of polypeptides. Each subfraction may be assayed against the target molecule and the set from which  
10 the subfraction having the highest activity was derived is selected.

These methods further may comprise preparing a further group comprising a plurality of sets of polypeptides, each of the sets having in the previously defined common  
15 position the amino acid unit appearing in the previously defined common position in the previously selected set. Each of said further group of sets has a different amino acid unit in an additional, defined common position. The amino acid units in positions of the polypeptide which are not in a  
20 common position are randomized. In other embodiments of the invention this group may subfractionated to provide subfractions of the sets of polypeptides.

Each of said sets or subfractions of sets may be assayed for activity for the target molecule and the set  
25 having the highest activity, or the set from which the subfraction having the highest activity was derived, is selected. The preceding steps may be performed iteratively.

Methods of determining a polypeptide cassette having specific activity for a target molecule are also provided by  
30 the present invention. These methods involve preparing a group comprising a plurality of sets of polypeptides, each polypeptide comprising at least four amino acid units, by defining a common position in the polypeptides of the sets and synthesizing said sets of polypeptides such that each set has  
35 a different amino acid unit in said common position and the amino acid units which are not in the common position are randomized. Each of the sets are then assayed for activity for

- 9 -

a target molecule and the set having the greatest activity for the target molecule is selected. Thereafter, a further group is prepared comprising a plurality of sets of polypeptides, each of the sets having in the previously defined common position the amino acid unit appearing in the previously defined common position in the previously selected set. Each of said further group of sets has a different amino acid unit in an additional defined common position. The amino acid units in positions of the polypeptides which are not in a defined common position are randomized. Each set of said further group is assayed for specific activity for the target molecule and the set having the highest activity is selected. The preceding steps are performed iteratively to provide a polypeptide cassette having each position defined.

15 In other embodiments of the invention methods for determining a polypeptide having specific activity for a target molecule are provided comprising preparing a group comprising a plurality of sets of polypeptides, each polypeptide comprising at least one polypeptide cassette and at least one flanking region by defining a common position in a flanking region of the polypeptides of the sets and synthesizing said sets of polypeptides such that each set has a different amino acid unit in said common position and the amino acid units which are not in the common position are randomized. Each of the sets are then assayed for activity for a target molecule and the set having the greatest activity for the target molecule is selected.

These methods further comprise preparing a further group comprising a plurality of sets of polypeptides, each of the sets having in the previously defined common position the amino acid unit appearing in the previously defined common position in the previously selected set. Each of said further group of sets has a different amino acid unit in an additional, defined common position in the flanking region. The amino acid units in positions of the polypeptides which are not in a common position in the flanking region are randomized. Each of the sets of polypeptides are assayed for

- 10 -

specific activity for the target molecule and the set having the highest activity is selected. The preceding steps may be performed iteratively.

#### DETAILED DESCRIPTION OF THE INVENTION

5           The present invention is directed to non-enzymatic methods for determining oligomers which are active for a target molecule. In one embodiment of the present invention methods of determining oligonucleotides having specific binding affinity for a target molecule are provided. Another  
10       embodiment of the present invention provides methods determining oligonucleotides having enzymatic or catalytic activity for a target molecule. In still other embodiments of the present invention methods of determining polypeptides having specific binding affinity for a target molecule are  
15       provided. Methods of determining polypeptides having enzymatic or catalytic activity for a target molecule are also provided.

          In the context of the present invention an oligomer is a string of units linked together by chemically similar  
20       covalent linkages. Nucleic acids linked together via phosphodiester bonds or amino acids linked together via peptide bonds are examples of naturally occurring oligomers.

          In the context of this invention, the term "oligonucleotide" refers to a polynucleotide formed from  
25       naturally occurring bases and furanosyl groups joined by native phosphodiester bonds. This term effectively refers to naturally occurring species or synthetic species formed from naturally occurring subunits or their close homologs. The term "oligonucleotide" may also refer to moieties which have  
30       portions similar to naturally occurring oligonucleotides but which have non-naturally occurring portions. Thus, oligonucleotides may have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur-containing species which are  
35       known for use in the art. In accordance with some preferred embodiments, at least some of the phosphodiester bonds of the

- 11 -

oligonucleotide have been substituted with a structure which functions to enhance the stability of the oligonucleotide or the ability of the oligonucleotide to penetrate into the region of cells where the viral RNA is located. It is preferred that such substitutions comprise phosphorothioate bonds, phosphotriesters, methyl phosphonate bonds, short chain alkyl or cycloalkyl structures or short chain heteroatomic or heterocyclic structures. Most preferred are  $\text{CH}_2\text{-NH-O-CH}_2$ ,  $\text{CH}_2\text{-N(CH}_3\text{)-O-CH}_2$ ,  $\text{CH}_2\text{-O-N(CH}_3\text{)-CH}_2$ ,  $\text{CH}_2\text{-N(CH}_3\text{)-N(CH}_3\text{)-CH}_2$  and  $\text{O-N(CH}_3\text{)-CH}_2\text{-CH}_2$  structures where phosphodiester is  $\text{O-P-O-CH}_2$ ). Also preferred are morpholino structures. Summerton, J.E. and Weller, D.D., U.S. 5,034,506 issued July 23, 1991. In other preferred embodiments, such as the protein-nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone. P.E. Nielsen, et al., *Science* 1991 254 1497. In accordance with other preferred embodiments, the phosphodiester bonds are substituted with other structures which are, at once, substantially non-ionic and non-chiral, or with structures which are chiral and enantiomerically specific. Persons of ordinary skill in the art will be able to select other linkages for use in practice of the invention.

Oligonucleotides may also include species which include at least some modified base forms. Thus, purines and pyrimidines other than those normally found in nature may be so employed. Similarly, modifications on the furanosyl portion of the nucleotide subunits may also be effected, as long as the essential tenets of this invention are adhered to. Examples of such modifications are 2'-O-alkyl- and 2'-halogen-substituted nucleotides. Some specific examples of modifications at the 2' position of sugar moieties which are useful in the present invention are OH, SH,  $\text{SCH}_3$ , F, OCN,  $\text{O(CH}_2\text{)}_n\text{NH}_2$ ,  $\text{O(CH}_2\text{)}_n\text{CH}_3$  where n is from 1 to about 10;  $\text{C}_1$  to  $\text{C}_{10}$  lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl, Br, CN,  $\text{CF}_3$ ,  $\text{OCF}_3$ , O-, S-, or N-alkyl; O-, S-, or N-alkenyl;  $\text{SOCH}_3$ ,  $\text{SO}_2\text{CH}_3$ ;  $\text{ONO}_2$ ;  $\text{NO}_2$ ;  $\text{N}_3$ ;  $\text{NH}_2$ ; heterocycloalkyl;

- 12 -

heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a conjugate; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group  
5 for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. Sugar mimetics such as cyclobutyls may also be used in place of the pentofuranosyl group. Oligonucleotides may also comprise other modifications consistent with the  
10 spirit of this invention. Such oligonucleotides are best described as being functionally interchangeable with yet structurally distinct from natural oligonucleotides. All such oligonucleotides are comprehended by this invention so long as they effectively function as subunits in the  
15 oligonucleotide.

In the context of the present invention polypeptide refers to a plurality of joined amino acid units formed in a specific sequence from naturally occurring amino acids. Said amino acid units are generally linked together via peptide  
20 bonds. Naturally occurring subunits include the twenty commonly occurring amino acids, as well as other less common naturally occurring amino acids. Polypeptides, in the context of the present invention, also refers to moieties which are similar to polypeptides but which have non-naturally occurring  
25 portions. Hence, polypeptides may have altered linkages or may be comprised of altered amino acid residues such as D-amino acids or other modifications consistent with the spirit of the present invention. Such modified polypeptides have also been referred to in the art as polypeptide analogs.

30 The methods of the present invention are useful to determine oligomers which are specifically active for a target molecule. In the context of the present invention determine refers to concurrent identification of the sequence of an oligomer and the binding activity of the oligomer for a target  
35 molecule. Further, determine refers to the identification of oligomers having activity such as catalytic or enzymatic activity. In some instances, neither the oligomer sequence nor

- 13 -

its specific activity is known prior to performance of methods of the present invention. In other cases, while a particular oligomer sequence may be known, those skilled in the art may not recognize its activity for a particular target molecule.

- 5 In still other cases, activity of a known sequence for a particular target molecule may be optimized.

Oligomers of the present invention are assayed for specific activity for a target molecule. In some embodiments of the present invention, specific activity refers to binding  
10 affinity of said oligomers for a target molecule. In other embodiments of the present invention, specific activity encompasses binding affinity and further encompasses activity such as catalytic or enzymatic activity. As used herein, binding affinity refers to the ability of the oligomer to bind  
15 to a target molecule via hydrogen bonds, van der Waals interactions, hydrophobic interactions, or otherwise. For example, an oligonucleotide may have binding affinity for another oligonucleotide to which it is complementary, i.e., to which it has the ability to hybridize due to Watson-Crick  
20 base pair attraction.

Target molecules of the present invention may include any of a variety of biologically significant molecules. Target molecules may be nucleic acid strands such as significant regions of DNA or RNA. Target molecules may  
25 also be proteins, carbohydrates, or glycoproteins. In some preferred embodiments of the present invention, said target molecule is a protein such as an immunoglobulin, receptor, receptor binding ligand, antigen or enzyme and more specifically may be a phospholipase, tumor necrosis factor,  
30 endotoxin, interleukin, plasminogen activator, protein kinase, cell adhesion molecule, lipxygenase, hydrolase or transacylase. In other preferred embodiments of the present invention said target molecules may be important regions of the human immunodeficiency virus, *Candida*, herpes viruses,  
35 papillomaviruses, cytomegalovirus, rhinoviruses, hepatitises, or influenza viruses. In still further preferred embodiments of the present invention said target molecule is ras 47-mer

stem loop RNA, the TAR element of human immunodeficiency virus or the gag-pol stem loop of human immunodeficiency virus (HIV) or the HIV tat protein. Still other targets may induce cellular activity. For example, a target may induce  
5 interferon.

In some aspects of the present invention, a target protein may be identified based upon the fact that proteins bind to free aldehyde groups while nucleic acids do not. Thus, a sampling of proteins which have been identified as  
10 potential targets may be bound to solid supports having free aldehyde groups such as nitrocellulose filters. For example, up to 96 proteins may be bound in individual wells of a 96-well nitrocellulose filter manifold. In some embodiments of the present invention sequential concentrations of protein may  
15 be tested to determine the effect of lowering the protein target concentration. Thereafter, an identical detectably labeled oligonucleotide group may be incubated with each protein sample under binding conditions. The preparation of labeled oligonucleotide groups is described herein. The  
20 support is washed and the presence or absence of binding is detected whereby binding indicates that the oligonucleotide group has specific activity for a given protein. As will be apparent to one skilled in the art, methods of detection of binding will be dependent upon the label used.

25 In the present invention, a group of sets of random oligomers is prepared. Oligomers may be prepared by procedures known to those skilled in the art. Specifically, oligonucleotides and polypeptides may be prepared by solid state synthesis or by other means known to those skilled in  
30 the art. For example, oligonucleotides may be prepared using standard phosphoramidite chemistry. In some embodiments of the present invention oligomer groups may further be labeled, such as by radiolabeling or fluorescent labeling. For example, an oligonucleotide group may be labeled at the 5'  
35 termini of the oligonucleotides using [ $\gamma$ - $^{32}$ P] ATP and T4 polynucleotide kinase. Labeled oligomer groups may be useful



- 15 -

in a number of assays which can not be performed using unlabeled oligomer groups.

Oligomers of each set may be of predetermined length. It is preferred that such oligomers be from about 4 to about 50 units in length. It is more preferred that such oligomers be from 4 to about 40 units in length. It is also preferred for some embodiments of the present invention that less than about 10 units of an oligomer are randomized. In some cases, it may be desirable to provide an oligomer which initially comprises 6, 7, or 8 random units.

In some embodiments of the present invention, the length of said oligomer need not be constant throughout the procedure. For example, an 8-mer may be assayed to determine the sequence having highest binding affinity for a target molecule. Subsequently, the 8-mer may be extended and tested as a 15-mer to determine the 15-mer sequence having the highest binding affinity for the target molecule.

Groups of the present invention are made up of a plurality of sets which may remain constant throughout the procedure. From about three to about twenty sets can make up each group. In one preferred embodiment of the present invention four sets make up each group. In another embodiment of the present invention twenty sets make up each group. Alternatively, three sets may make up each group.

The number of sets that make up each group is dependent upon the number of possible distinct chemically similar units which exist for any one species of molecule. For example, an oligonucleotide group may be comprised of four sets since there are four similar units making up the nucleic acid species, i.e. guanine, adenine, cytosine, thymine or adenine, guanine, cytosine and uracil. Alternatively, an oligonucleotide group may be comprised of more than four sets representing for example, the four commonly occurring bases and additional modified bases. Twenty sets may make up a polypeptide group, representing the twenty commonly occurring amino acids, lysine, arginine, histidine, aspartic acid, glutamic acid, glycine, asparagine, glutamine, cysteine,

- 16 -

serine, threonine, tyrosine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine and tryptophan. Greater than twenty sets may also make up a polypeptide group if uncommon or modified amino acids are included in the assay.

- 5 Subgroups of basic units may also determine the number of sets in any one group. For example, in procedures to determine a particular polypeptide, sets may represent acidic, basic and neutral amino acid units, i.e. three sets. The number of sets in groups in any one procedure need not remain constant
- 10 throughout, but may fluctuate. For example, in a one group there may be three sets representing three types of polypeptides and in a next group there may be twenty sets representing each commonly occurring amino acid.

- The use of additional units such as nucleotide or
- 15 amino acid analogs may be preferred in some instances where it is desirable to increase the complexity of the group of oligomers. The complexity of a group may be calculated by the formula  $P \times P^N$  where  $P$  is the number of different units used and  $N$  is the number of positions in an oligomer which are
- 20 randomized. The complexity of a set ( $Q$ ) is represented by the formula  $P^N$ . Table 1 illustrates the change in group complexity as a result of the increase in the number of analogs used. Of course, the number of different units used also determines the number of sets prepared.

-17-

TABLE 1

Group Structure = NNN X NNN

	Number of different analogues used (P)	Complexity of each set (Q) (P <sup>Q</sup> )	Total Group Complexity (P · P <sup>Q</sup> )
5	4	4 <sup>6</sup> = 4096	4 x 4096 = 16,384
	5	5 <sup>6</sup> = 15,625	5 x 15,625 = 78,125
	6	6 <sup>6</sup> = 46,656	6 x 46,656 = 279,936
	7	7 <sup>6</sup> = 117,649	7 x 117,649 = 823,543
	8	8 <sup>6</sup> = 262,144	8 x 262,144 = 2,097,152
10	9	9 <sup>6</sup> = 531,441	9 x 531,441 = 4,782,969
	10	10 <sup>6</sup> = 1,000,000	10 x 1,000,000 = 10,000,000

- 18 -

Each of the sets in a group has a different unit in a common position of said oligomer. For example, in determining an oligonucleotide, only one of four sets will contain an adenine in a common position, only one set will  
5 contain a guanine in a common position, etc. The remaining positions in each set of oligonucleotides are comprised of any combination of random basic units.

In further embodiments of the present invention, common positions are comprised of multiple oligomer positions.  
10 For example, for a 9-mer, one common position may be the third position of the 9-mer, or the common position may be comprised of the third position and the fourth position of the 9-mer.

In some aspects of the invention, it may be desirable to begin a procedure by unrandomizing central  
15 regions of an oligomer as opposed to end regions, such as the 3' or 5' regions of an oligonucleotide or the carboxy or amino terminal regions of a polypeptide, since it has been found that in some cases defining a central position had a greater affect on specific activity of an oligomer than did  
20 defining an end region during a similar stage of a determination. For example, in Example 8 an attempt to fix a 3' position did not yield results that distinguished the sets, whereas a position in the center of the oligomer was fixed to yield results which were detectable.

25 Furthermore, there is a complexity limit to the detectability of activity (signal-to-noise), especially in oligomers having a high percentage of unrandomized positions. It is likely that with largely unstructured, conformationally dynamic oligomers, a plethora of relatively weak specific  
30 activity towards many target molecules will result. As discussed, this may be improved by increasing the number of units used. An additional method of increasing specific activity of a group of oligomers is to constrain the oligomer sterically. For example, an oligonucleotide may be sterically  
35 constrained by providing complementary ends at the 3' and 5' termini of the region of interest, which region comprises

- 19 -

randomized positions. The complementary ends will hybridize to form a secondary structure.

The detectable specific activity may also be enhanced by the determination and/or use of an oligomer "cassette". An oligomer cassette is a oligomer for which a sequence has been determined. The cassette may be comprised of a sequence of known significance, or may be determined such as by the procedures of the present invention. As used herein an oligonucleotide cassette is a defined oligonucleotide sequence and a polypeptide cassette is a defined polypeptide sequence. In some embodiments of the present invention an oligomer may comprise at least one oligomer cassette and at least one flanking region of unrandomized positions. In other embodiments of the present invention an oligomer may be comprised of more than one cassette wherein each cassette is flanked by at least one region of randomized positions. For example, a oligonucleotide cassette of known sequence may be flanked at the 3' terminus, the 5' terminus, or both the 3' and 5' termini.

In some embodiments of the present invention it may also be desirable to subfractionate a group of oligomers to provide subfractions of the sets of oligomers, thus delimiting the degree of complexity that is assayed at one time. This both diminishes the amount of total material that must be used in a determination in order to have sufficient representation of all individual sequences and it also enhances the signal to noise ratio of the assay by starting with oligomer sets enriched in the most active sequences. Any physical-chemical or functional characteristic, combined with an appropriate separation modality may be used to empirically subfractionate a group, thereby resulting in (or deriving) numerous distinct subfractions of diverse character, and diminished complexity. It is theorized that if a particular fit sequence or sequences exist within the original group for a particular target, it will be found enriched in a limited number of the reduced complexity subfractions.

- 20 -

One skilled in the art would be apprised of the broad selection of appropriate selection modalities which are available. The strategy followed will of course depend upon the properties of the elements of the oligomer group. It will  
5 further be appreciated by one skilled in the art that as the number of group elements increases and the structural and chemical diversity enlarges, there will be a greater selection of separation strategies leading to increased subfractionation capacity. By way of example, it is envisioned that novel  
10 oligomers may be resolved into subfractions by any one or a combination of size, positive or negative charge, hydrophobicity and affinity interactions. Many chromatographic and analytical instrumental methods are known to those skilled in the art which may be effectively applied  
15 to the separation strategies encompassed herein.

In some embodiments of the invention each set of oligomers is assayed for desired activity. In other embodiments of the present invention, identical empirical assays of subfractions of oligomer sets described above are  
20 performed in order to identify those subfractions having the strongest activity as indicated by a strong signal to noise ratio. The set having the highest activity or the set from which the subfraction having the highest activity is derived is selected and further unrandomization may be performed if  
25 desired.

Specific activity may be detected by methods known to those skilled in the art. Appropriate assays will be apparent to one skilled in the art and oligomer concentration, target molecule concentration, salt concentration,  
30 temperature, buffer and buffer concentration may be altered to optimize a particular system. In some preferred embodiments of the present invention, binding conditions simulate physiological conditions. In other preferred embodiments of the present invention binding occurs in a  
35 buffer of from about 80 mM to about 110 mM sodium chloride and from about 10 to about 15 mM magnesium chloride. Oligomers may also generally be assayed for catalytic or enzymatic activity.

- 21 -

Gel shift assays may be used to visualize binding of an oligomer to a target molecule. In accordance with methods of the present invention, radiolabelled target molecule bound to oligomer of the present invention may be run  
5 on a gel such as a polyacrylamide gel. Bound target molecule has less mobility than unbound target molecule, and therefore will not migrate as far on the gel. The radioactive label allows visualization of the "shift" in mobility by standard procedures for example, by means of X-ray radiography or by  
10 using a phosphorimager (Molecular Dynamics). In other embodiments of the present invention a gel shift assay may be performed wherein an unlabeled target molecule may be bound to radiolabelled oligomer.

Radiolabeled oligomer may also be useful for the  
15 streptavidin capture of a biotinylated-target bound to an oligomer. For example, a target may be biotinylated prior to incubation with radioactively labeled random oligomer sets. Each set is thereafter incubated with the target under identical conditions and the target molecule is captured on  
20 streptavidin-coated beads. Consequently any oligomer which bound to the target will also be captured. Streptavidin-coated beads are available commercially such as for example, streptavidin-coated manganese particles available from Promega. The beads are washed and the reaction may be  
25 reequilibrated to further enrich the "winning" sequence. The percent of oligomers from each set which bound is determined by the amount of radioactivity remaining after wash. Measuring radioactivity in a sample may be performed by a number of methods known in the art. For example, the amount  
30 of radioactivity may be determined directly by counting each sample, using for example a scintillation counter. Samples may also be run on a polyacrylamide gel, the gel may be placed under x-ray film and a densitometric reading of the autoradiogram may be taken.

35 Assays are not limited to detecting binding affinity but may also detect other desired activities such as catalytic or enzymatic activity. Some embodiments of the present

- 22 -

invention provide for detection of specific activity by a cell culture assay. For example, inhibition of cell adhesion may indicate binding of oligomer to a target molecule involved in cell adhesion. In further embodiments of the present invention further groups of sets are prepared. Each of said further groups have a selected number of sets of oligomers. Sets of further groups have in a previously defined common position, units appearing in the previously defined common position in previously selected set. Each set of the further sets has a different unit in an additional defined common position. The units in the positions of the oligomer that are not in a common position are randomized.

For example, in one group, the previously selected set may be comprised of an adenine in the previously defined common position. A further group may retain said adenine in said previously defined common position, and at another defined common position each set in said further group may be comprised of a different unit, either adenine, guanine, thymine or cytosine. The units in the positions of the oligomer that are not in a common position are randomized.

In further embodiments of the present invention, common positions are comprised of multiple oligomer positions as described above. For example, for a 9-mer, the one common position may be the third position of the 9-mer, or the common position may be comprised of the third position and the fourth position of the 9-mer.

Procedures useful for increasing the complexity of an oligomer group, and/or increasing specific activity of an oligomer described previously are equally applicable to said further groups. Thus, oligomer groups may be comprised of multiple units, may be sterically constrained and may be subfractionated prior to assaying for specific activity. Furthermore, oligomers of further groups may comprise one or more cassettes.

Sets are again assayed for desired activity. The steps described above may be performed iteratively.



- 23 -

The following examples are illustrative, but not limiting of the invention.

#### Example 1

##### Synthesis of DNA Oligonucleotides

- 5           Unmodified DNA oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.  $\beta$ -cyanoethyldiisopropyl phosphoramidites may be purchased from Applied Biosystems (Foster City, CA).

#### 10   Example 2

##### Synthesis of RNA Oligonucleotides

- Unmodified RNA oligonucleotides having random base sequences were synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using modified standard phosphoramidite  
15   chemistry synthesis with oxidation by iodine. The standard synthesis was modified by increasing the wait step after the pulse delivery of tetrazole to 900 seconds.  $\beta$ -cyanoethyldiisopropyl phosphoramidites were purchased from Applied Biosystems (Foster City, CA). The bases were  
20   deprotected by incubation in methanolic ammonia overnight. Following base deprotection, the oligonucleotides were dried *in vacuo*. The t-butyldimethylsilyl protecting the 2' hydroxyl was removed by incubating the oligonucleotide in 1M tetrabutylammoniumfluoride in tetrahydrofuran overnight. The  
25   RNA oligonucleotides were further purified on C<sub>18</sub> Sep-Pak cartridges (Waters, Division of Millipore Corp., Milford, MA) and ethanol precipitated.

#### Example 3

##### Synthesis of Phosphorothioate Oligonucleotides

- 30           Phosphorothioate oligonucleotides represent a class of oligonucleotide analog that is substantially nuclease resistant. Phosphorothioate RNA oligonucleotides and phosphorothioate DNA oligonucleotides were synthesized according to the procedure set forth in Examples 1 and 2

- 24 -

respectively, replacing the standard oxidation bottle by a 0.2M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for stepwise thiation of phosphite linkages. The thiation cycle wait step was increased to 68 seconds and is followed by the capping step.

#### Example 4

##### Synthesis of 2'-O-alkyl Phosphorothioate Oligonucleotides

2'-O-methyl phosphorothioate oligonucleotides were synthesized according to the procedures set forth in Example 3 substituting 2'-O-methyl  $\beta$ -cyanoethyldiisopropyl phosphoramidites (Chemgenes, Needham, MA) for standard phosphoramidites and increasing the wait cycle after the pulse delivery of tetrazole and base to 360 seconds. Similarly, 2'-O-propyl, 2'-O-phenyl and 2'-O-nonyl phosphorothioate oligonucleotides may be prepared by slight modifications of this procedure.

#### Example 5

##### Preparation of Pyrene Oligonucleotide Analogs

Oligonucleotides were prepared by incorporating 2'-aminopentoxadenosine at desired sites. The oligonucleotides were dissolved in 0.2M NaHCO<sub>3</sub> buffer and treated with 50 fold excess of N-hydroxysuccinimide ester of pyrene-1-butyric acid dissolved in dimethylformamide. The resultant mixture is incubated at 37°C for 4-5 hours and the conjugate is purified by reverse phase HPLC followed by desalting in a G-25 Sephadex column.

#### Example 6

##### Synthesis of Oligonucleotide Having Randomized Positions

Four columns of the DNA synthesizer were packed with a mixture containing an equal amount of adenosine(A)-, cytidine(C)-, guanosine(G)- and uracil(U)-controlled pore glass (CPG, Chemgenes, Needham, MA). At coupling steps where a given nucleotide base was desired, the defined phosphoramidite was delivered to each column. At each

- 25 -

"random" coupling step, an equimolar mixture of all four phosphoramidites was delivered to each column.

### Example 7

#### Preparation of Radiolabeled Groups

- 5 Oligonucleotide groups prepared in accordance with Example 1 through 6 may be radiolabeled using [ $\gamma$ - $^{32}$ P] ATP and T4 polynucleotide kinase as described in Maniatis, et al. "Molecular Cloning: A Laboratory Manual" (Cold Spring Harbor, NY).

### 10 Example 8

#### Effect of Site of Unrandomization on Activity

Twenty-four sets of phosphorothioate oligonucleotides were prepared in accordance with Examples 3 and 6 as set forth in Table 2.

15

TABLE 2

	Set 1	ANNNNN	Set 13	NNNANN
	Set 2	CNNNNN	Set 14	NNNCNN
	Set 3	GNNNNN	Set 15	NNNGNN
	Set 4	TNNNNN	Set 16	NNNTNN
20	Set 5	NANNNN	Set 17	NNNNAN
	Set 6	NCNNNN	Set 18	NNNNCN
	Set 7	NGNNNN	Set 19	NNNNGN
	Set 8	NTNNNN	Set 20	NNNNTN
	Set 9	NNANNN	Set 21	NNNNNA
25	Set 10	NNCNNN	Set 22	NNNNNC
	Set 11	NNGNNN	Set 23	NNNNNG
	Set 12	NNTNNN	Set 24	NNNNNT

- Each of the sets is tested for activity against a target molecule to determine which order of unrandomization gives the highest initial specific activity.

### Example 9

#### Preparation of a Biotin Oligonucleotide Group

- An oligonucleotide group having the sequence TNNXNNNTB, wherein N is any of A, G, C, or U, X is one of A, G, C and U and B is biotin, is prepared in accordance with Examples 3 and 6. The sequence is designed with flanking thymidines to provide sites for radiolabeling. A control

- 26 -

having the sequence TNNNXNNNT is also prepared in accordance with Examples 3 and 6.

**Example 10****Preparation of Oligonucleotide Group comprising Nucleotide  
5 Analogs.**

Oligonucleotide groups having the sequence NNNXNNNU are prepared in accordance with Example 1 and 6 incorporating one or more of the nucleoside analogs 2'-O-nonyl adenosine, N6-imidazolylpropyl guanosine, 2'-O-aminopentyl cytidine, 2'-O-  
10 pentyl-adenosine, 2'-O-pentyl-guanosine, 2'-O-pentyl-cytidine, 3'-terminal 2'-O-methyl uridine and 6-amino-2-hydroxymethyl-1-hexanol. The nucleosides, 2'-O-nonyl adenosine, N6-imidazolylpropyl guanosine, 2'-O-aminopentyl cytidine, 2'-O-pentyl-adenosine, 2'-O-pentyl-guanosine, 2'-O-pentyl-cytidine,  
15 3'-terminal 2'-O-methyl uridine were prepared by modification of the methods described in PCT US91/00243 filed 1/11/91. 6-amino-2-hydroxymethyl-1-hexanol is available commercially. The nucleosides are modified to provide the corresponding phosphoramidite by methods known to those skilled in the art.

**20 Example 11****Gel-shift Assay of Random 2-O-Methyl Oligonucleotide Binding  
to ras RNA Target**

The ras 47-mer stem/loop RNA was enzymatically synthesized, <sup>32</sup>P end-labeled according to standard procedures,  
25 and gel-purified. 2'-O-Methyl oligonucleotide analog libraries comprising four sets were prepared in accordance with Examples 4 and 6. Each set was tested for binding against the RNA target and a "set K<sub>D</sub>" was determined in accordance with the following procedure.

30 In a first round the ras RNA target was incubated at a concentration of approximately 10 pM with each of the four random 2'-O-methyl oligonucleotide sets, at concentrations of 5, 10, 50 and 100 μM in a buffer consisting of 100 mM NaCl and 10 mM MgCl<sub>2</sub>. The hybridization was carried out for four hours  
35 at 37°C, followed by electrophoretic separation of bound vs.

- 27 -

unbound material on a 20% acrylamide gel in Tris-Borate buffer (TBE) plus 50 mM NaCl, run at 25 W for four hours. The gel was dried and the radioactive bands were visualized on a phosphorimager (Molecular Dynamics). The ras stem/loop target alone is the lowest band visible on the gel (highest mobility). As this target binds oligonucleotide (non-radioactive), the mobility of the ras target is decreased, shifting the band to a higher position on the gel (complex). In Figure 2A no binding is seen for the oligonucleotide sets NNNNGNNNN or NNNNUNNNN, but NNNNANNNN shows a slight shift at 100  $\mu$ M and NNNNCNNNN shifts more than 50% of the target to the bound form at 50  $\mu$ M oligonucleotide concentration.

The protocol was then repeated in Round 2. The ras RNA target was incubated at a concentration of approximately 10 pM with each of the four random oligonucleotide sets synthesized according to the method described above, at concentrations of 1 and 10  $\mu$ M to provide the gel image of Figure 2B which shows that oligonucleotide sets NNNNCNANN, NNNNCNGNN and NNNNCNUNN show minimal binding. NNNNCNCNN shows a shift of more than 25% of the target at 1  $\mu$ M and about 50% of the target at 10  $\mu$ M. In Round 3 the ras RNA target was incubated with the random oligonucleotide sets at concentrations of 0.1 and 1  $\mu$ M to provide the gel image of Figure 2C where only NNCNCNCNN showed binding, exhibited by a shift of greater than 50% of the target.

Table 3 sets forth results of nine rounds performed to determine the "winner" sequence which binds to the ras RNA target.  $K_D$  are in  $\mu$ M.

- 28 -

TABLE 3

Round	Sequence*	Q''	K <sub>D</sub>			
			A	C	G	U
1	NNNNXNNNN	65,536	22	10	>100	>100
5 2	NNNNCNXNN	16,384	>10	4	>10	>10
3	NNXNCNCNN	4,096	>10	0.5	>10	>10
4	NNCXCNCNN	1,024	>10	0.15	>10	>10
5	NNCCCXCNN	256	0.08	>1	0.4	>1
6	NNCCCACXN	64	0.05	>0.5	0.08	>0.5
10 7	NXCCCACAN	16	>0.1	>0.1	0.03	>0.1
8	NGCCCACAX	4	0.05	0.02	0.05	0.042
9	XGCCCACAC	1	0.03	0.05	0.02	0.01

\* wherein N is any of A, C, G or T; '' Q is set complexity.

As illustrated in Table 3, it was not difficult to distinguish the set with the lowest K<sub>D</sub> (μM) at each round of synthesis and screening.

As expected for oligonucleotide hybridization reactions, positions near the center of the oligonucleotide had a greater effect on the K<sub>D</sub> than positions on the extreme 5' or 3' ends. For example, an attempt to fix the 3' position in round 4 did not yield results that distinguished the sets. An alternative position was selected for round 4 which yielded a clear winner, and then the sequence was elucidated from the center of the oligomer to the ends. The final oligonucleotide selected by the procedure is complementary to the single stranded loop region of the target RNA.

#### Example 12

##### ELISA for Detection of Inhibition of Herpes Simplex Virus-1

ELISA for detection of HSV-1 envelope glycoprotein B (gB) was performed by infection of normal dermal fibroblast cells (NHDF, Clonetics) with HSV-1 (KOS) at a multiplicity of infection of 0.05 PFU/cell. Following virus adsorption, cells were washed and treated with growth media containing

- 29 -

oligonucleotide. Oligonucleotides were tested in triplicate wells at four concentrations. Cells were fixed 48 hours postinfection and assayed for the presence of HSV-1 gB antigen by ELISA. Standard deviation were typically within 10%.

5 **Example 13**

**Inhibition of Herpes Simplex Virus-1 Activity by Phosphorothioate Oligonucleotide Sets**

A group of 65,536 unique 8-mers in 4 sets of 16,348 was prepared in accordance with Examples 3 and 6 each was  
10 screened for activity against human herpes simplex virus type 1 (HSV-1) in cell culture in accordance with the procedure described in Example 9. As illustrated in Table 4, antiviral activity was observed with increasing potency at each round of synthesis and screening, with no difficulty discerning the  
15 most active set (in bold) in each round.

-30-

TABLE 4

Round	Sequence	Q <sup>**</sup>	IC <sub>50</sub> (μM) when X =			
			A	C	G	T
1	NNNXXNNN	16,348	>100	>100	70	>100
5	NNNGNNNX	4,096	>100	>100	30	>100
3	NNNGNXNG	1,024	>100	>100	15	>100
4	NXNGNGNG	256	30	30	5	20
5	XGNGNGNG	64	20	20	1.5	20
6	GGNGXGNG	16	10	10	1.5	10
10	GGXGGGNG	4	1.3	1.3	0.5	1.3
8	GGGGGGXG	1	0.7	0.7	1.1	0.4

\* where N is any of A, C, G or T; \*\* where Q is set complexity.



- 31 -

The oligonucleotide set containing a fixed guanine had the most activity in every round of HSV screening except the last round, resulting in selection of a guanine at nearly all fixed positions.

#### 5 Example 14

##### Optimization of G<sub>4</sub> Core Containing 8-mer Oligonucleotide for HSV-1 Antiviral Activity

To determine the optimal 8-mer containing a G<sub>4</sub> core, a oligonucleotide group was designed as shown in Table 5,  
10 using the oligonucleotide cassette GGGG.

TABLE 5

	Sequence*	Most Active X =	IC <sub>50</sub> (μM)
	NNGGGGNX	A	2.5
	NNGGGGXA	T	1.1
15	XNGGGGTA	G	0.8
	GXGGGGTA	C	0.8

\* N is any of A, G, T or C.

As shown in Table 5, optimization of the sequences surrounding the G<sub>4</sub> core produced a 3 fold increase in  
20 antiviral activity in four rounds of synthesis and screening, suggesting that although the G<sub>4</sub> core is the most important component of the activity, potency can be modulated by the flanking sequences.

#### Example 15

##### 25 Assay for Detection of Inhibition of Human Immunodeficiency Virus

The human T-lymphoblastoid CEM cell line was maintained in an exponential growth phase in RPMI 1640 with 10% fetal calf serum, glutamine, and antibiotics. On the day  
30 of the assay, the cells were washed and counted by trypan blue exclusion. These cells (CEM-IIIB) were seeded in each well of a 96-well microtiter plate at  $5 \times 10^3$  cells per well.

- 32 -

Following the addition of cells to each well, the compounds were added at the indicated concentrations and serial half log dilutions. Infectious HIV-1<sub>mb</sub> was immediately added to each well at a multiplicity of infection determined to give complete cell killing at 6 days post-infection. Following 6 days of incubation at 37° C, an aliquot of supernatant was removed from each well prior to the addition of the tetrazolium dye XTT to each well. The XTT was metabolized to a formazan blue product by viable cells which was quantitatively measure spectrophotometrically with a Molecular Devices Vmax Plate Reader. The XTT assay measures protection from the HIV-induced cell killing as a result of the addition of test compounds. The supernatant aliquot was utilized to confirm the activities determined in the XTT assay. Reverse transcriptase assays and p24 ELISA were performed to measure the amount of HIV released from the infected cells. Protection from killing results in an increased optical density in the XTT assay and reduced levels of viral reverse transcriptase and p24 core protein.

#### 20 Example 16

##### Inhibition of Human Immunodeficiency Virus by Phosphorothioate Oligonucleotide Sets

A group of 65,536 unique 8-mers in 4 sets of 16,348 each were prepared in accordance with Examples 3 and 6 and screened for activity in accordance with Example 12. The compound sets are described in Table 6. Table 6 sets forth the IC<sub>50</sub> (μM) for four oligonucleotide sets.

TABLE 6

	<u>Set</u>	<u>Sequence*</u>	<u>IC<sub>50</sub> (μM)</u>
30	A	NNNN A NNN	inactive
	B	NNNN C NNN	inactive
	C	NNNN G NNN	5
	D	NNNN T NNN	inactive

\* where N is any of A, C, G, or T.

- 33 -

Set C sowed 50% inhibition of HIV-induced cytopathic effects at 5  $\mu$ M, while the other compound sets were inactive at concentration up to 25  $\mu$ M.

#### Example 17

##### 5 Assay for the Detection of Inhibition of Cytomegalovirus

Confluent monolayer cultures of human dermal fibroblasts were treated with oligonucleotide sets at the indicated concentrations in serum-free fibroblast growth media. After overnight incubation at 37 °C, culture medium  
10 containing oligonucleotide was removed, cells were rinsed and human cytomegalovirus was added at a multiplicity of infection of 0.1 pfu/cell. After a 2 hour adsorption at 37 °C, virus was removed and fresh fibroblast growth medium containing oligonucleotide sets at the indicated concentrations was  
15 added. Two days after infection, old culture medium was removed and replaced with fresh fibroblast growth medium containing oligonucleotide sets at the indicated concentrations. Six days after infection media was removed, and cells fixed by addition of 95% ethanol. HCMV antigen  
20 expression was quantitated using an enzyme linked immunoassay. Primary reactive antibody in the assay was a monoclonal antibody specific for a late HCMV viral protein. Detection was achieved using biotinylated goat anti-mouse IgG as secondary antibody followed by reaction with streptavidin  
25 conjugated B-galactosidase. Color was developed by addition of chlorophenol red B-D-galactopyranoside and absorbance at 575 nanometers measured using an ELISA plate reader. Results are expressed as percent of untreated control and were calculated as follows:

$$\%Control = 100 \times \frac{\text{infected cell control} - \text{treated cells}}{\text{infected cell control} - \text{uninfected cell control}}$$

- 34 -

**Example 18****Inhibition of Cytomegalovirus by Phosphorothioate Oligonucleotide Sets**

A group of 65,536 unique phosphorothioate 8-mers in  
5 4 sets of 16,438 were prepared in accordance with Examples 3  
and 6 and screened for activity against the human  
cytomegalovirus in accordance with Example 14. The compound  
sets A (NNNNANNN), B (NNNNGNNN), C (NNNNCNNN) and D  
(NNNNTNNN), where N is any of A, G, C or T, were screened at  
10 a range of concentration from 10 to 200  $\mu$ M. The results shown  
in Figure 3 show that compound set B had the greatest activity  
against cytomegalovirus, causing approximately 20% inhibition  
at a 100 $\mu$ M dose and 90% inhibition at a 200 $\mu$ M dose. Sets A,  
B and D exhibited minimal to no antiviral activity.

**15 Example 19****Assay to Detect Inhibition of Influenza A Virus**

Vero cells were pretreated overnight with randomer  
sets by direct addition to the media at 10  $\mu$ M and 100 $\mu$ M  
concentrations. After overnight treatment cells were infected  
20 with influenza A/PR/8 at a MOI of 0.05. Following infection  
cells were incubated for 48 hours in the presence of  
oligonucleotide. After incubation cells were fixed with  
methanol and air dried. Monolayers were then assayed by ELISA  
for matrix protein. Primary antibody was a monoclonal  
25 antibody specific for matrix protein of influenza A virus  
(B020 Bioproducts for Science). Second antibody was goat  
antimouse IgG conjugated to alkaline phosphatase (BRL,  
Bethesda, MD). Substrate was ATTO-PHOS reagent, JBL.  
Fluorescence was measured using a Millipore Cytofluor 2300  
30 with excitation at 450 nm and emission read at 580 nm.

- 35 -

**Example 20****Inhibition of Influenza Virus by Phosphorothioate Oligonucleotide Sets**

A group of 65,536 unique phosphorothioate 8-mers in 4 sets of 16,438 was prepared in accordance with Examples 3 and 6 and was screened for activity against the Influenza A virus as described in Example 16. The compound sets A (NNNNANNN), B (NNNNGNNN), C (NNNNCNNN) and D (NNNNTNNN), where N is any of A, G, C or T, were screened at 10  $\mu$ M and 100  $\mu$ M. The results as shown in Figure 4 show that sets C and D had the greatest antiviral activities, set C exhibited approximately 50% inhibition and set D exhibited approximately 35% inhibition of viral activity. A and B exhibited minimal activity.

Data are the arithmetic mean and standard error of triplicate data points of a single experiment.

**Example 21****Determination of Oligonucleotides which Induce Interferon**

A phosphorothioate oligonucleotide group comprising 20 sets having the sequence N N N N X N N N where N is any of adenine, guanine, cytosine or thymidine and X is one of adenine, guanine, cytosine or thymidine is prepared in accordance with Examples 3 and 6. The sets are set forth in Table 7.

25

**TABLE 7**

Set	Modification
1-4	natural
5-8	2'-O-methyl
9-12	2'-O-propyl
13-16	2'-O-pentyl
17-20	2'-O-nonyl

30

An ELISA is performed to determine the set which is most effective to induce interferon. The nucleotide in the

- 36 -

most effective set is fixed and sets having the fifth position fixed and the fourth position one of adenine, guanine, cytosine or thymidine is prepared. An ELISA is performed to determine the set which is most effective to induce  
5 interferon. The steps are repeated until all of the positions are determined.

**Example 22****Gel Shift Assay of Random Pyrene Oligonucleotide Sets Binding  
10 to HIV TAR Element**

The HIV TAR element is a structured RNA found on the 5'-end of all HIV transcripts. A gel shift has been used to analyze the binding of four oligonucleotide sets to the HIV TAR element (illustrated in Figure 5A). The target RNA has a  
15 three base bulge that is required for binding of the transcriptional activation protein tat. The oligonucleotides set forth in Table 8 were prepared in accordance with Examples 5 and 6, each containing a pyrene analog (indicated by A').

**TABLE 8**

20	SEQ ID NO:
SET 1 N N N A' N A N N N N 3	
SET 2 N N N A' N C N N N N 4	
SET 3 N N N A' N G N N N N 2	
SET 4 N N N A' N U N N N N 5	

25 The assay uses a 15pM concentration of the radioactively labeled target and an 0.1, 1, 10, and 100  $\mu$ M concentrations of each set. Binding of molecules from the set to the target results in a slower mobility complex. Set 3 binds best to TAR as illustrated in Figure 5B wherein 100  $\mu$ M  
30 of the oligonucleotide set caused a shift of approximately 50% of the target. 100  $\mu$ M of the oligonucleotide set 2 caused a shift of approximately 25% of the target. Sets 1 and 4 caused minimal shift of the target. The sixth position will be fixed

- 37 -

as a G and another position unrandomized in the second round of synthesis and assays.

### Example 23

#### Random Oligonucleotide Set Binding to HIV gag-pol Triple 5 Strand

Binding to double stranded DNA or RNA is possible by formation of a three stranded complex with the incoming third strand binding in the major groove of the duplex RNA or DNA. The molecular nature of the interaction between the  
10 oligomer and target need not be known in order to practice the technique. Thus, it is possible that novel interactions between oligomers and DNA or RNA will be responsible for binding. Figure 6 illustrates a double stranded RNA structure from HIV known as the gag-pol stem loop (Vickers and Ecker,  
15 Nucleic Acids Research). One of the limitations in the design of triple strand interactions is the need to have a long stretch of homopurines as a target. The 3' (right) side of the gag-pol stem loop is homopurine except for a pair of cytosines near the bottom of the stem. To determine the best  
20 oligonucleotide to bind to the gag-pol stem loop, a group of RNA oligonucleotide sets was designed to bind to the purine-rich strand of the gag-pol stem-loop by Hoogsteen base pairing and prepared in accordance with Examples 2 and 6. At the position of the two cytosines the sequence was randomized to  
25 provide the sequences set forth in Table 9. Binding to the gag-pol stemloop was measured by gel shift analysis as previously described in Example 8 with the following modifications: the radiolabeled gag-pol RNA was incubated with the oligonucleotide in 100mM NaCl, 25 mM TRIS acetate  
30 pH5, 2mM Mg Cl<sub>2</sub>, 1mM spermidine. The gel was a 15% acrylamide with 50 mM NaCl 2mM MgCl<sub>2</sub> added to the running buffer.

The results in Table 9 show that in round 1 the oligonucleotide set CCCUCCCCNUC (SEQ ID NO: 8) had the greatest affinity for the target with a  $K_D$  of 50. In the  
35 second round the C was fixed in the eighth position and the ninth position was determined. The oligonucleotide

- 38 -

CCCUUCCCCUC (SEQ ID NO: 12) had the greatest affinity for the target in the ninth round with a  $K_D$  of 1. Thus, a triple strand-binding sequence can be optimized.

TABLE 9

<b>5 Round 1</b>				
	<b>Set</b>	<b>Sequence</b>	<b><math>K_D</math> (<math>\mu</math>M)</b>	<b>SEQ ID NO:</b>
	A <sub>1</sub>	CCCUUCCANUC	>100	6
	B <sub>1</sub>	CCCUUCCGNUC	>100	7
	C <sub>1</sub>	CCCUUCCCNUC	50	8
<b>10</b>	D <sub>1</sub>	CCCUUCCUNUC	100	9
<b>Round 2</b>				
	<b>Set</b>	<b>Sequence</b>	<b><math>K_D</math> (<math>\mu</math>M)</b>	<b>SEQ ID NO:</b>
	A <sub>2</sub>	CCCUUCCCAUC	10	10
	B <sub>2</sub>	CCCUUCCCGUC	10	11
<b>15</b>	C <sub>2</sub>	CCCUUCCCCUC	1	12
	D <sub>2</sub>	CCCUUCCCUUC	10	13

**Example 24****Random Oligonucleotide Binding to Transcription Factors**

A radiolabeled oligonucleotide group was prepared  
**20** having the sequence NNGGGGNX wherein N is any of A, G, T or C and X is one or A, G, T or C as described in Examples 3, 6 and 7. The group was screened for binding to the HIV tat protein, which is a transcription factor produced by the virus as described in Example 24. Binding activity was observed.

**25 Example 25****Random 2'-O-Methyl Oligonucleotide Binding to Endothelin-1**

Receptor and radiolabeled ligand were supplied in a kit obtained from DuPont/NEN. Assays were performed according to the manufacturer's instructions. A random 2'-O-  
**30** methyl group was prepared in accordance with Examples 4 and 6 to provide four sets having the sequences GCGNNNANNNNNNCGC (SEQ ID NO: 14); GCGNNNGNNNNNCGC (SEQ ID NO:15); GCGNNNCNNNNNCGC (SEQ ID NO:16); GCGNNNUNNNNNNCGC (SEQ ID NO:



- 39 -

17) where N is any of A, G, C or U. Each set was diluted to 100  $\mu$ M in an assay buffer provided in the kit, then incubated with the receptor and ligand as per the manufacturer's protocol. Following the incubation, ligand- bound receptor  
 5 was separated from unbound by vacuum filtration through glass filters. The bound ligand was then eluted from the filter in scintillation fluid and counted in a scintillation counter. Receptor and ligand were incubated with an excess of unlabeled  
 10 (NSB) to the filters and with no oligonucleotide set (zero) to establish the level of complete binding.

The results shown in Table 10 indicate that set B was most active against Endothelin-1.

TABLE 10

15		CPM	NET CPM	% I
	NSB	284	-	-
	zero	1421	1140	100
	A	1223	939	82
	B	1200	916	80
20	C	1347	1063	93
	D	1330	1046	92

**Example 26****Random 2'-O-Methyl Oligonucleotide Binding to Leukotriene B<sub>4</sub>**

Receptor and radiolabeled ligand were supplied in  
 25 a kit obtained from DuPont/NEN. Assays were performed according to the manufacturer's instructions. A random 2'-O-methyl group was prepared in accordance with Examples 4 and 6 to provide four sets having the sequences GCGNNNANNNNNNCGC (SEQ ID NO: 14); GCGNNNGNNNNNCGC (SEQ ID NO:15);  
 30 GCGNNNCNNNNNCGC (SEQ ID NO:16); GCGNNNUNNNNNNCGC (SEQ ID NO: 17) where N is any of A, G, C or U. Each set was diluted to 100  $\mu$ M in an assay buffer provided in the kit, then incubated with the receptor and ligand as per the manufacturer's protocol. Following the incubation, ligand- bound receptor

- 40 -

was separated from unbound by vacuum filtration through glass filters. The bound ligand was then eluted from the filter in scintillation fluid and counted in a scintillation counter. Receptor and ligand were incubated with an excess of unlabeled  
 5 ligand in order to establish the level of non-specific binding (NSB) to the filters and with no oligonucleotide set (zero) to establish the level of complete binding. The results shown in Table 11 indicate that set D. was most active against leukotriene B4.

10

TABLE 11

		CPM	NET CPM	% I
	NSB	383	-	-
	zero	1063	680	100
	A	989	606	89
15	B	953	570	84
	C	900	517	76
	D	894	511	75

**Example 27**

**Phosphorothioate and 2'-O-Methyl Oligonucleotide Binding to**  
 20 **the Viral Receptors CD4**

Two groups of oligonucleotides were prepared. A phosphorothioate oligonucleotide group was prepared in accordance with Examples 3 and 6. A 2'-O-methyl oligonucleotide group was prepared in accordance with Examples  
 25 4 and 6. Both groups have the sequence NNNNTNNNN where N is any of A, C, G or T.

100 pmoles of each group of random oligonucleotides is 5' end labeled to high specific activity with [ $\gamma$ -<sup>32</sup>P] ATP and T4 polynucleotide kinase. Each labeled group is reacted  
 30 with the protein CD4 at room temperature in a buffer consisting of 100 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 10% glycerol, 1 mM DTT, and 20 mM HEPES (pH=7.9). poly dI•dC is added as indicated as a non-specific competitor. After 1 hour protein bound oligonucleotide is separated from unbound by

- 41 -

electrophoresis on a 6% native acrylamide gel in 1X TBE buffer. The results of the phosphorothioate oligonucleotide assay is shown in Figure 7 and indicates binding of the oligonucleotide to the protein (at the arrow). No binding has  
 5 was detected by the 2'-O-methyl set. Binding has been observed with the phosphorothioate pool against the tat protein.

#### Example 28

#### Preparation of Random Group of Polypeptides and Assay for 10 Binding Thereof

Polypeptides may be used in the practice of this invention. Monomer amino acids are easily oligomerized into peptides using the appropriate precursor chemicals and instruments available to those skilled in the art, such as  
 15 those that can be purchased from Applied Biosystems.

The first round of synthesis is as follows:

	Position	1	2	3	4	5	6	7	8	9
	Set 1	X	X	X	X	B	X	X	X	X
	Set 2	X	X	X	X	A	X	X	X	X
20	Set 3	X	X	X	X	W	X	X	X	X
	Set 4	X	X	X	X	L	X	X	X	X

TABLE 12

where A is defined as an acidic amino acid, B is defined as  
 25 a basic amino acid, W is defined as a neutral amino acid, L is defined as a lipophilic amino acid, and X is defined as any amino acid from the above identified group.

Each of the above sets is tested for inhibition of cell adhesion using a cell culture assay in which the ICAM-1  
 30 mediated binding of cells is measured as described. Dustin, M.L. and Springer, T.A. *J. Cell Biol.* 1988, 107, 321. The set showing greatest inhibition of cell adhesion at the lowest polypeptide concentration is selected.

The protocol is repeated, retaining the selected  
 35 amino acid at position 5, and sequentially testing each remaining position to reach an optimal binding sequence.

#### Example 29

- 42 -

### Identification of Oligonucleotide Sequence Using Streptavidin Capture of Biotinylated Target

0.2 $\mu$ M of a target oligonucleotide having the sequence 3'dBAB AGA CGT CTT GCG 5' (SEQ ID NO: 18) wherein B is biotin, was incubated for 30 minutes at room temperature with 10 $\mu$ M of a radiolabeled 2'-O-methyl oligonucleotide group prepared in accordance with Examples 4, 6 and 7 having the sequence NNN NCN CNN wherein N is any of adenine, cytosine, thymidine or guanine, and 0.1 $\mu$ M of a radioactively labeled oligonucleotide complementary to the target (dTCTGCAGAACGC; SEQ ID NO: 19). The target oligonucleotide and any bound radioactively labeled oligonucleotide was captured on streptavidin-coated magnasphere beads (Promega), the beads were washed, and supernatant removed. The captured radioactively labeled oligonucleotide was removed from the beads and run on a polyacrylamide gel. Figure 8 sets forth a sample gel which indicates that a "winner" can be separated from an excess of random sequence oligonucleotides. The procedure was repeated. In lane 1 was run a 1:10 dilution of the original solution prior to capture. Lane 2 is the supernatant diluted 1:10. Lane 3 is the bound material from the first round. A band of "winner" sequence is apparent, migrating to the first arrow. Lanes 4 and 5 are the supernatant (1:10 dilution) and bound material from the second round, respectively. The second round results in a "winner" band of greater purity. Lanes 6 and 7 are the supernatant (1:10 dilution) and bound material from the third round, respectively. The supernatant does not contain any radiolabeled oligonucleotides. The third round results in a "winner" band with little to no non-specific oligonucleotide.

### Example 30

#### Identification of a Protein Target

A group of oligonucleotides having the sequence NNNNNNNN wherein N is any one of adenine, guanine, thymidine or cytosine is prepared in accordance with Examples 3 and 6.

- 43 -

The group is labeled using [ $\gamma$ - $^{32}$ P] ATP and T4 polynucleotide kinase.

In individual wells of a 96-well nitrocellulose filter manifold, the following proteins are incubated in a solution of phosphate buffer saline: plasminogen activator A<sub>2</sub>, tumor necrosis factor  $\alpha$ , tumor necrosis factor  $\beta$  and gp120. Phosphate buffer saline only is added to a control well. The filter is washed. An aliquot of the labeled group of oligonucleotides is added to each well and incubated at room temperature for 10 minutes. The filter is washed and the counts in each well over background are counted to determine whether binding of the oligonucleotide to the protein occurred.

#### Example 31

#### 15 Determination of Phosphorothioate Oligonucleotide Having Binding Affinity for Nitrocellulose Bound Proteins

An oligonucleotide analog group comprising four sets of oligonucleotides eight positions in length is prepared in accordance with Examples 3 and 6 and each set is tested for binding against the nitrocellulose-bound proteins identified in accordance with Example 27. The set having the highest affinity for each protein, as indicated by counts per well is the "winner set" for each protein. Results of the first round are as set forth in Table 13.

25

TABLE 13

Position	1	2	3	4	5	6	7	8	Protein winner
Set 1	N	N	N	N	A	N	N	N	plasminogen activator A <sub>2</sub> , tumor necrosis factor $\alpha$
Set 2	N	N	N	N	G	N	N	N	no winner
30 Set 3	N	N	N	N	C	N	N	N	gp120
Set 4	N	N	N	N	T	N	N	N	tumor necrosis factor $\beta$

- 44 -

The filter is washed and wells counted. In a second round, the A is fixed in the fifth position and the sets (NNNAANNN), (NNNGANNN), (NNNCANNN), and (NNNTANNN) are prepared for testing in the wells containing plasminogen activator A<sub>2</sub> and tumor necrosis factor  $\alpha$ . Similarly, sets in which the C is fixed in the 5th position or a T is fixed in the 5th position are prepared for testing in the gp120 and tumor necrosis factor  $\beta$  wells, respectively. By the eighth round, "winner" sequences for all four target proteins are determined.

#### Example 32

#### Determination of an Oligonucleotide Having Binding Affinity for a Target Protein using Subfractionated Sets of Oligonucleotides

An oligonucleotide analog group comprising four sets of oligonucleotides eight positions in length is prepared in accordance with Examples 3 and 6 wherein each of the sets has a different one of adenine, guanine, thymidine and cytosine in the 5th position, and the rest of the positions are randomized to provide the group: NNNNANNN, NNNNGNNN, NNNNTNNN, and NNNNCNNN. Each set is subfractionated by charge with an anion exchange column. Each subfraction is tested for affinity for the target protein by gel shift assay. The subfraction from the set having an adenine in the 5th position has the highest binding affinity. In a further round, the 5th position is fixed to contain an adenine in the 5th position, and each set has a different nucleotide in the fourth position to provide the group NNNAANNN, NNNTANNN, NNNGANNN, and NNNCANNN. The sets are again subfractionated by charge with an anion exchange column and the subfractions are tested for affinity for the target protein by gel shift assay. The steps are repeated until each position is determined.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Ecker, David J.  
Anderson, Kevin  
Bruice, Thomas A.  
Davis, Peter  
Driver, Vickie  
Hanecak, Ronnie C.  
Vickers, Timothy A.  
Wyatt, Jaqueline
- (ii) TITLE OF INVENTION: Synthetic Unrandomization of Oligomer  
Fragments
- (iii) NUMBER OF SEQUENCES: 21
- (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and Norris  
(B) STREET: One Liberty Place - 46th Floor  
(C) CITY: Philadelphia  
(D) STATE: PA  
(E) COUNTRY: U.S.A.  
(F) ZIP: 19103
- (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER:

46

(B) FILING DATE:  
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 749,000  
(B) FILING DATE: 23-AUG-1991

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Gaumont, Rebecca R.  
(B) REGISTRATION NUMBER: 35,152  
(C) REFERENCE/DOCKET NUMBER: ISIS-0653

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 215-568-3100  
(B) TELEFAX: 215-568-3439

(2) INFORMATION FOR SEQ ID NO:1:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGUGGUGGUG GGGCCCGUCG GUGUGGGCAA GAGUGCGCUG ACCAUCC

(2) INFORMATION FOR SEQ ID NO:2:

47



47

10

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 10 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(ix) FEATURE:  
    (A) NAME/KEY: misc\_feature  
    (B) LOCATION: 4  
    (D) OTHER INFORMATION: /note= "pyrene analog of adenine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

NNNANGNNNN

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 10 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(ix) FEATURE:  
    (A) NAME/KEY: misc\_feature  
    (B) LOCATION: 4  
    (D) OTHER INFORMATION: /note= "pyrene analog of adenine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

NNNANNNNN

10

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "pyrene analog of adenine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

NNNANNNNN

10

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(ix) FEATURE:  
 (A) NAME/KEY: misc\_feature  
 (B) LOCATION: 4  
 (D) OTHER INFORMATION: /note= "pyrene analog of adenine"

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

NNNANUNNNN

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

11

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CCCUUCCANU C

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCCUUCCGNU C

11

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CCCUUCCGNU C

11

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

51

11

CCCUUCCUNU C

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 11 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: RNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CCCUUCCCAU C

11

## (2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 11 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: RNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCCUUCCCGU C

11

## (2) INFORMATION FOR SEQ ID NO:12:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 11 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCCUUCCCCU C

11

(2) INFORMATION FOR SEQ ID NO:13:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 11 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CCCUUCCCCU C

11

(2) INFORMATION FOR SEQ ID NO:14:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 base pairs  
(B) TYPE: nucleic acid

52-1

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCGNNNANN NNCGC

15

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GCGNNNGNN NNCGC

15

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

52-2

15

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCGNNNCNNN NNCGC

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCGNNNUNNN NNCGC

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

15



52-3

13

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

AAGACGTCTT GCG

(2) INFORMATION FOR SEQ ID NO:19:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

12

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TCTGCAGAAC GC

(2) INFORMATION FOR SEQ ID NO:20:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

52-4

29

GCCAGAUUCG AGCCUGGGAG CUCUCUGGC

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CUGGCCUUC UACAAGGGA GGCCAG

26

SUBSTITUTE SHEET

- 53 -

What is claimed is:

1. A method for determining an oligonucleotide having specific activity for a target molecule comprising the steps of:

5 (a) preparing a group comprising a plurality of sets of oligonucleotides, each oligonucleotide comprising at least four base units by:

(i) defining a common position in the oligonucleotides of the sets, and

10 (ii) synthesizing said sets of oligonucleotides such that each set has a different base unit in said common position, the base units which are not in said common position being randomized;

(b) assaying each of the sets for activity  
15 against the target molecule; and

(c) selecting the set having the highest activity.

2. The method of claim 1 further comprising:

(d) preparing a further group comprising a  
20 plurality of sets of oligonucleotides, each of the sets having in the previously defined common position the base units appearing in the previously defined common position in the previously selected set; each set of said further group of sets having a different base unit in an additional, defined  
25 common position, the base units in the positions of the oligonucleotides which are not in a defined common position being randomized;

(e) assaying each of the sets for specific activity for the target molecule; and

30 (f) selecting the set having the highest activity.

3. The method wherein the steps of claim 2 are performed iteratively.

- 54 -

4. The method of claim 1 wherein said group is comprised of from about three to about twenty sets.

5. The method of claim 1 wherein said group is comprised of four sets.

5           6. The method of claim 1 wherein said oligonucleotides are from 4 to about 20 nucleotide units in length.

7. The method of claim 1 wherein said group of sets of oligonucleotides is detectably labeled.

10           8. The method of claim 7 wherein the group of sets of oligonucleotides is radiolabelled.

9. The method of claim 1 wherein said assay is a gel shift assay, streptavidin capture of biotinylated target, filter binding assay or affinity chromatography.

15           10. The method of claim 1 wherein the group of sets of oligonucleotides are sterically constrained.

11. The method of claim 1 wherein said target molecule is a nucleic acid.

20           12. The method of claim 1 wherein said target molecule is a carbohydrate.

13. The method of claim 1 wherein said target molecule is a protein.

14. The method of claim 1 wherein said target molecule is a glycoprotein.

- 55 -

15. The method of claim 1 wherein the target molecule is an immunoglobulin, receptor, receptor binding ligand, antigen, enzyme, or transcription factor.

16. The method of claim 1 wherein the target  
5 molecule is a phospholipase, tumor necrosis factor, endotoxin, interleukin, leukotriene, plasminogen activator, protein kinase, cell adhesion molecule, lipoxxygenase, hydrolase, transacylase, or transcription factor.

17. The method of claim 1 wherein the target  
10 molecule is a region of *Candida*, papilloma virus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, influenza virus or cytomegalovirus.

18. The method of claim 1 wherein the target molecule is an RNA molecule or fragment thereof.

15 19. The method of claim 1 wherein the target molecule is a region of a human immunodeficiency virus.

20. The method of claim 1 wherein the target molecule is the TAR element of human immunodeficiency virus.

21. The method of claim 1 wherein the target  
20 molecule is the gag-pol stem loop of human immunodeficiency virus.

22. The method of claim 1 wherein the target molecule is the ras 47 base pair stem loop.

23. The method of claim 1 wherein the target  
25 molecule is a region of a herpes virus.

24. The method of claim 1 wherein the target molecule is a region of cytomegalovirus.

- 56 -

25. The method of claim 1 wherein the target molecule is a region of an influenza virus.

26. The method of claim 1 wherein the target molecule is endothelin-1.

5 27. The method of claim 1 wherein the target molecule is leukotriene B-4.

28. The method of claim 1 wherein the target molecule is gp120.

10 29. The method of claim 1 wherein the target molecule is the HIV tat protein.

30. The method of claim 1 wherein the target molecule induces the production of interferon.

31. A method for identifying a target molecule comprising the steps of:

- 15 (a) binding a selected group of molecules to solid support;
- (b) incubating solid support with a group of detectably labeled oligonucleotides having all positions randomized, under binding conditions;
- 20 (c) detecting the presence or absence of binding wherein binding of the oligonucleotide group indicates activity of the oligonucleotide for one or more target molecules.

32. The method of claim 31 further comprising the 25 steps of :

- (d) preparing a group comprising a plurality of sets of oligonucleotides, each oligonucleotide comprising at least four base units by:
- (i) defining a common position in the 30 oligonucleotides of the sets, and

- 57 -

(ii) synthesizing said sets of oligonucleotides such that each set has a different base unit in said common position, the base units which are not in said common position being randomized;

5 (e) assaying each of the sets for activity against said target molecules; and

(f) selecting the set having the highest activity.

10 33. The method of claim 32 further comprising the steps of:

(g) preparing a further group comprising a plurality of sets of oligonucleotides, each of the sets having in the previously defined common position the base units appearing in the previously defined common position in the previously  
15 selected set; each set of said further group of sets having a different base unit in an additional, defined common position, the base units in the positions of the oligonucleotides which are not in a defined common position being randomized;

20 (h) assaying each of the sets for specific activity for said target molecules; and

(i) selecting the set having the highest activity.

34. The method wherein the steps of claim 33 are performed iteratively.

25 35. A method for determining an oligonucleotide having specific activity for a target molecule comprising the steps of:

(a) preparing a group comprising a plurality of sets of oligonucleotides, each oligonucleotide comprising at least  
30 four base units by:

(i) defining a common position in the oligonucleotides of the sets, and

(ii) synthesizing said sets of oligonucleotides such that each set has a different base unit in said common

- 58 -

position, the base units which are not in said common position being randomized;

(b) subfractionating the group of oligonucleotides to provide subfractions of the sets of oligonucleotides;

5 (c) assaying each of the subfractions for activity against the target molecule; and

(d) selecting the set from which the subfraction having the highest activity was derived.

36. The method of claim 35 further comprising:

10 (e) preparing a further group comprising a plurality of sets of oligonucleotides, each of the sets having in the previously defined common position the base unit appearing in the previously defined common position in the previously selected set; each set of said further group of  
15 sets having a different base unit in an additional, defined common position, the base units in the positions of the oligonucleotides which are not in a defined common position being randomized;

(f) subfractionating the group of the  
20 oligonucleotides to provide subfractions of the sets of oligonucleotides;

(g) assaying each of the subfractions for activity against the target molecule; and

(h) selecting the set from which the subfraction  
25 having the highest activity was derived.

37. The method wherein the steps of claim 36 are performed iteratively.

38. A method for determining an oligonucleotide cassette having specific activity for a target molecule  
30 comprising the steps of:

(a) preparing a group comprising a plurality of sets of oligonucleotides, each oligonucleotide comprising at least four base units by:



- 59 -

(i) defining a common position in the oligonucleotides of the sets, and

(ii) synthesizing said sets of oligonucleotides such that each set has a different base unit in said common position, the base units which are not in said common position being randomized;

(b) assaying each of the sets for activity against the target molecule;

(c) selecting the set having the highest activity;

10 (d) preparing a further group comprising a plurality of sets of oligonucleotides, each of the sets having in the previously defined common position the base unit appearing in the previously defined common position in the previously selected set; each set of said further group of  
15 sets having a different base unit in an additional, defined common position, the base units in the positions of the oligonucleotides which are not in a defined common position being randomized;

(e) assaying each of the sets of said further group  
20 for specific activity for the target molecule; and

(f) selecting the set having the highest activity; said steps (d), (e), and (f) being performed iteratively to provide said cassette having each position defined.

39. A method for determining an oligonucleotide  
25 having specific activity for a target molecule comprising the steps of:

(a) preparing a group comprising a plurality of sets of oligonucleotides, each oligonucleotide comprising at least one predefined oligonucleotide cassette and at least one  
30 flanking region by:

(i) defining a common position in a flanking region of the oligonucleotides of the sets, and

(ii) synthesizing said sets of oligonucleotides such that each set has a different base unit in said common  
35 position, the base units which are not in said defined positions being randomized;

- 60 -

(b) assaying each of the sets for activity against the target molecule; and

(c) selecting the set having the highest activity.

40. The method of claim 39 further comprising:

5 (d) preparing a further group comprising a plurality of sets of oligonucleotides, each of the sets having in the previously defined common position the base unit appearing in the previously defined common position in the previously selected set; each set of said further group of  
10 sets having a different base unit in an additional, defined common position, the base units in the positions of the oligonucleotides which are not in a defined position being randomized;

(e) assaying each of the sets for specific activity  
15 for the target molecule; and

(f) selecting the set having the highest activity.

41. The method of claim 40 performed iteratively.

42. The method of claim 39 wherein said cassette is prepared in accordance with claim 38.

20 43. A method for determining a polypeptide having specific activity for a target molecule comprising the steps of:

(a) preparing a group comprising a plurality of sets of polypeptides, each polypeptide comprising at least four  
25 amino acid units, by:

(i) defining a common position in the polypeptides of the sets, and

(ii) synthesizing said sets of polypeptides such that each set has a different amino acid unit in said  
30 common position, the amino acid units which are not in said common position being randomized;

(b) assaying each of the sets for activity for the target molecule; and

- 61 -

(c) selecting the set having the highest activity.

44. The method of claim 43 further comprising:

(d) preparing a further group comprising a plurality of sets of polypeptides, each of the sets having in the previously defined common position the amino acid unit appearing in the previously defined common position in the previously selected set; each set of said further group of sets having a different amino acid unit in an additional, defined common position, the amino acid units in the positions of the polypeptides which are not in a common position being randomized;

(e) assaying each of the sets for specific activity for the target molecule; and

(f) selecting the set having the highest activity.

45. The method wherein the steps of claim 44 are performed iteratively.

46. The method of claim 43 wherein said group comprises from about three to about twenty sets.

47. The method of claim 43 wherein said polypeptides are from about 12 to about 20 amino acid units in length.

48. The method of claim 43 wherein said target molecule is a nucleic acid.

49. The method of claim 43 wherein said target molecule is a carbohydrate.

50. The method of claim 43 wherein said target molecule is a protein.

51. The method of claim 43 wherein said target molecule is a glycoprotein.

52. The method of claim 43 wherein the target is an immunoglobulin, receptor, receptor binding ligand, antigen, or enzyme.

53. The method of claim 43 wherein the target is  
5 a phospholipase, tumor necrosis factor, endotoxin, interleukin, leukotriene, plasminogen activator, protein kinase, cell adhesion molecule, lipoxxygenase, hydrolase, or transacylase.

54. The method of claim 43 wherein the target is  
10 a region of *Candida*, papilloma virus, Epstein-Barr virus, rhinovirus, hepatitis, human immunodeficiency virus, herpes simplex virus, influenza virus or cytomegalovirus.

55. A method for determining a polypeptide having specific activity for a target molecule comprising the steps  
15 of:

(a) preparing a group comprising a plurality of sets of polypeptides, each polypeptide comprising at least four base units by:

(i) defining a common position in the  
20 polypeptides of the sets, and

(ii) synthesizing said sets of polypeptides such that each set has a different amino acid unit in said common position, the base units which are not in said common position being randomized;

25 (b) subfractionating the group of polypeptides to provide subfractions of the sets of polypeptides;

(c) assaying each of the subfractions for activity against the target molecule; and

(d) selecting the set from which the subfraction  
30 having the highest activity was derived.

56. The method of claim 55 further comprising:

- 63 -

- (e) preparing a further group comprising a plurality of sets of polypeptides, each of the sets having in the previously defined common position the amino acid unit appearing in the previously defined common position in the previously selected set; each set of said further group of sets having a different amino acid unit in an additional, defined common position, the amino acid units in the positions of the polypeptides which are not in a defined common position being randomized;
- 10 (f) subfractionating the group of the polypeptides to provide subfractions of the sets of polypeptides;
- (g) assaying each of the subfractions for activity against the target molecule; and
- (h) selecting the set from which the subfraction  
15 having the highest activity was derived.

57. The method wherein the steps of claim 56 are performed iteratively.

58. A method for determining a polypeptide cassette having specific activity for a target molecule comprising the  
20 steps of:

- (a) preparing a group comprising a plurality of sets of polypeptides, each polypeptide comprising at least four amino acid units by:
- (i) defining a common position in the  
25 polypeptides of the sets, and
- (ii) synthesizing said sets of polypeptides such that each set has a different amino acid unit in said common position, the amino acid units which are not in said common position being randomized;
- 30 (b) assaying each of the sets for activity against the target molecule;
- (c) selecting the set having the highest activity;
- (d) preparing a further group comprising a plurality of sets of polypeptides, each of the sets having in  
35 the previously defined common position the amino acid unit

- 64 -

appearing in the previously defined common position in the previously selected set; each set of said further group of sets having a different amino acid unit in an additional, defined common position, the amino acid units in the positions  
5 of the polypeptides which are not in a defined common position being randomized;

(e) assaying each of the sets of said further group for specific activity for the target molecule; and

(f) selecting the set having the highest activity;  
10 said steps (d), (e), and (f) being performed iteratively to provide said cassette having each position defined.

59. A method for determining a polypeptide having specific activity for a target molecule comprising the steps of:

15 (a) preparing a group comprising a plurality of sets of polypeptides, each polypeptide comprising at least one predefined polypeptide cassette and at least one flanking region by:

(i) defining a common position in a flanking region  
20 of the polypeptides of the sets, and

(ii) synthesizing said sets of polypeptides such that each set has a different amino acid unit in said common position, the amino acid units which are not in said defined position being randomized;

25 (b) assaying each of the sets for activity against the target molecule; and

(c) selecting the set having the highest activity.

60. The method of claim 59 further comprising:

(d) preparing a further group comprising a  
30 plurality of sets of polypeptides, each of the sets having in the previously defined common position the amino acid units appearing in the previously defined common position in the previously selected set; each set of said further group of sets having a different amino acid unit in an additional,  
35 defined common position, the amino acid unit in the positions

- 65 -

of the polypeptides which are not in a defined position being randomized;


(e) assaying each of the sets for specific activity for the target molecule; and

5 (f) selecting the set having the highest activity.

61. The method of claim 60 performed iteratively.




62. The method of claim 59 wherein said cassette is prepared in accordance with claim 58.

1/8


***Fig. 1***




2/8

***Fig. 2A******Fig. 2B******Fig. 2C***

3/8

**Fig. 3**

4/8

**Fig. 4**

5/8

G G  
U G  
C A  
C · G  
G · C  
A · U  
C U G · C  
U A · U  
G · C  
A · U  
C · G  
C · G  
G · C

Fig. 5A

SEQ ID NO: 20




Fig. 5B

C-A  
A      A  
U      G  
C:G  
C:G  
U:A  
U:A  
C:G  
C:G  
G:C  
G:C  
U:A  
C:G

**Fig. 6**






Fig. 7

8/8

*Fig. 8*

## INTERNATIONAL SEARCH REPORT

International application No.

CT/US92/07121

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : C12Q 1/68, 1/00; G01N 33/53, 33/566, 33/559; C12P 21/06

US CL : 435/6, 7.1, 69.1; 436/501, 515

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1, 69.1; 436/501, 515

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
APS, Medline, Biosis, CA**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO, A, 91/12331 (VENTON) 22 August 1991, see pages 8-15.	1-62
Y	WO, A, 87/01374 (PIECZENIK) 12 March 1987, see the abstract, see pages 1-9.	1-62

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* *A* *E* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be part of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *Z*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	--	--------------------------	--

Date of the actual completion of the international search

23 September 1992

Date of mailing of the international search report

07 OCT 1992

Name and mailing address of the ISA/  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

DAVID R. PRESTON

Facsimile No. NOT APPLICABLE

Telephone No. (703) 205-0100